Chemed Corporation

CHE Healthcare Medical Care Facilities

Chemed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 4.06% from fiscal 2024.

Revenue
+10.6%
EPS
+23.1%
Free cash flow
−45.3%

Quarter to September 2026, against a year earlier

533.55 15.09 −2.75%
Market cap
$7.0B
P/E
25.5×
Fwd P/E
24.0×
Dividend yield
0.47%
F-score
6/9
Altman Z
11.69
Beneish M
−2.76
Dividend safety
100/100

Chemed Corporation (CHE) EV/EBITDA

Alert me on EV/EBITDA

As of 5 November 2026, Chemed Corporation (CHE) trades at a EV/EBITDA of 16.3×. Over the past ten years it has ranged from 9.1× (January 2015) to 33.2× (May 2018); the current reading is higher than 33% of that period. That is above the Medical Care Facilities industry median of 11.9× and above the Healthcare sector median of 8.4×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 15.3× (16.35%)
FY2024 18.3× (14.63%)
FY2023 21.5× 14.07%
FY2022 18.8× (10.75%)
FY2021 21.1× 11.27%
FY2020 19.0× (19.62%)
FY2019 23.6× 44.01%
FY2018 16.4× (39.23%)
FY2017 27.0× 111.62%
FY2016 12.7× 7.96%

Quarterly newest first

Period EV/EBITDA Change
Sep 2026 15.5× 3.11%
Jun 2026 15.0× 12.73%
Mar 2026 13.3× (13.26%)
Dec 2025 15.3× (0.53%)
43 more quarters

Against its own ten years

Low 9.1× High 33.2×
Ten-year median 18.4×
Current reading's percentile 33

EV/EBITDA against peers

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on CHE